Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Lymphoma, Mantle-Cell 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma, Follicular 3Leukemia, Prolymphocytic, B-Cell 3Leukemia, Lymphocytic, Chronic, B-Cell 3Leukemia, Myeloid, Acute 2Stomach Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Lymphoma, T-Cell 1Lymphoma, Extranodal NK-T-Cell 1Leukemia, Prolymphocytic, T-Cell 1Leukemia, Large Granular Lymphocytic 1Immunoblastic Lymphadenopathy 1Enteropathy-Associated T-Cell Lymphoma 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1

Interventions

Gemcitabine 205130-nm albumin-bound paclitaxel 84Albumin-Bound Paclitaxel 57pembrolizumab 43Fluorouracil 41Leucovorin 34Oxaliplatin 33Capecitabine 25Nivolumab 22Irinotecan 19Bevacizumab 17Paclitaxel 16Cyclophosphamide 15Cetuximab 15Taxes 13Erlotinib Hydrochloride 13Drug Therapy 13Carboplatin 12irinotecan sucrosofate 11Injections 10Cisplatin 9fludarabine 8ALT-803 8spartalizumab 7olaparib 7avelumab 7Pemetrexed 7Docetaxel 7ruxolitinib 6TH 302 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Pancreatic Neoplasms × Sensitivity and Specificity × Clear all
NCT02839954 2016-12-06

CAR-pNK Cell Immunotherapy in MUC1 Positive Relapsed or Refractory Solid Tumor

PersonGen BioTherapeutics (Suzhou) Co., Ltd.

Phase 1/2 Unknown
10 enrolled
GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡